Company intelligence / Profile preview

Metrolink

Ownership: Private
Development stage: Commercial

Overview

Metro International Biotech has developed a comprehensive portfolio of proprietary NAD+ precursors aimed at increasing cellular NAD+ levels, which decline with age. Their lead compound, MIB‑626, has demonstrated robust preclinical data supporting its broad therapeutic potential and is currently in Phase 2 clinical trials. The company has synthesized over 100 novel enhancers and built a strong IP position with scalable manufacturing capabilities for solid oral dosage forms

Therapeutic areas: OtherMetabolic Disorders
Modalities: Small moleculeNAD+ precursorSynthetic nucleoside analogs
Industry: Biotech

Beyond the preview

Go deeper on Metrolink.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metrolink.

Explore the full profile